Immuneering CorporationIMRXNASDAQ
Loading
EBITDA Margin Over TimeStrong
Percentile Rank67
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
0.00%
↑ 100% vs avg
Percentile
P67
Within normal range
Average
-2711.13%
Historical baseline
PeriodValueYoY Change
20250.00%-
20240.00%-
20230.00%+100.0%
2022-16238.45%-901.4%
2021-1621.52%-120.4%
2020-735.58%-92.4%
2019-382.35%-